ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag policy disease medicine evolution

Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
blue-gloved hands pipetting from test tube
What’s Next for Ancient DNA Studies After the Nobel?
Mary Prendergast, The Conversation | Oct 5, 2022 | 4 min read
The award highlights tremendous opportunities for aDNA as well as challenges related to rapid growth, equity, and misinformation.
An illustration of green bacteria floating above neutral-colored intestinal villi
The Inside Guide: The Gut Microbiome’s Role in Host Evolution
Catherine Offord | Jul 1, 2021 | 10+ min read
Bacteria that live in the digestive tracts of animals may influence the adaptive trajectories of their hosts.
Policy Aspects Of Science Dominate 1994 AAAS Meeting
Franklin Hoke | Feb 6, 1994 | 4 min read
About 5,000 scientists are expected to attend the 1994 annual meeting of the American Association for the Advancement of Science, to be held in San Francisco February 18-23. * John Gibbons, Assistant to the President of the United States for Science and Technology, and Director of the Office of Science and Technology Policy: "Science, Technology, and the Clinton Administration." * "Health Care Reform and Advances in Medicine":
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Science and Politics in 2012
Bob Grant | Dec 19, 2012 | 4 min read
This year, US politics was dominated by the run-up to October elections, with science policy issues playing a role here and elsewhere around the world.
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager | May 27, 2019 | 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
Opinion: Ethical Boundaries Needed on the Uses of Synthetic DNA
John D. Loike and Robert Pollack | Mar 1, 2019 | 4 min read
A newly expanded genetic alphabet that includes four synthetic nucleotides highlights the need for strict boundaries on their use.
2022 Top 10 Innovations&nbsp;
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.

Run a Search

ADVERTISEMENT